Amphastar Pharmaceuticals (AMPH)
(Real Time Quote from BATS)
$41.71 USD
+0.60 (1.46%)
Updated Apr 29, 2024 10:52 AM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMPH 41.71 +0.60(1.46%)
Will AMPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPH
New Strong Sell Stocks for April 26th
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
Other News for AMPH
Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating
Commit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)
Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies